Literature DB >> 17033501

A projection of the impact of lipid-lowering therapy on high-risk employee disability and medical costs.

Xue Song1, Daniel M Huse, Setareh A Williams, Gerald M Borok, Ken McDonough, Ronald J Ozminkowski.   

Abstract

OBJECTIVE: The objective of this study was to examine the impact of introducing rosuvastatin calcium on direct and indirect costs among patients at high risk for coronary heart disease.
METHODS: An economic simulation model was developed to project the number of cardiovascular events and associated direct and indirect costs under varying treatment scenarios.
RESULTS: In an average-sized commercial health plan with 210,000 covered lives and 9,336 high-risk patients, an uptake of rosuvastatin by 11% of high-risk patients would result in eight fewer cardiovascular events, a net savings of 0.85 million dollars in direct medical costs and a net savings of 36,404 dollars in productivity loss over a period of 5 years. The overall reduction in total costs is equivalent to 1735 dollars per rosuvastatin-treated patient.
CONCLUSIONS: At current statin prices, the use of rosuvastatin could lead to fewer cardiovascular events and lower direct and indirect costs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033501     DOI: 10.1097/01.jom.0000237773.26755.78

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  2 in total

1.  Determining initial and follow-up costs of cardiovascular events in a US managed care population.

Authors:  Richard H Chapman; Larry Z Liu; Prafulla G Girase; Robert J Straka
Journal:  BMC Cardiovasc Disord       Date:  2011-03-16       Impact factor: 2.298

2.  Productivity loss and indirect costs associated with cardiovascular events and related clinical procedures.

Authors:  Xue Song; Ruben G W Quek; Shravanthi R Gandra; Katherine A Cappell; Robert Fowler; Ze Cong
Journal:  BMC Health Serv Res       Date:  2015-06-25       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.